Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | STAT1 | P42224 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18624161 | 0.86 | RAB9A (0.38) | RAB9AUSP2NPC1HPGDKDM4E | |
| SCHEMBL14837997 | 0.85 | RAB9A (0.44) | RAB9AUSP2NPC1HPGDKDM4E | |
| SCHEMBL14814895 | 0.80 | RAB9A (0.46) | RAB9AUSP2NPC1KDM4EALDH1A1 | |
| SCHEMBL14814305 | 0.79 | RAB9A (0.49) | RAB9AUSP2NPC1KDM4EALDH1A1 | |
| SCHEMBL14814430 | 0.77 | CREBBP (0.41) | RAB9ANPC1HPGDKDM4EALDH1A1 | |
| SCHEMBL11684104 | 0.76 | USP2 (0.70) | RAB9AUSP2KDM4EALDH1A1MEN1 | |
| SCHEMBL14814451 | 0.75 | USP2 (0.47) | RAB9AUSP2MAPK14MAPK13MAPK12 | |
| SCHEMBL14814120 | 0.75 | RAB9A (0.48) | RAB9AUSP2NPC1HPGDALDH1A1 | |
| SCHEMBL14814192 | 0.75 | USP2 (0.44) | RAB9AUSP2HPGDKDM4EALDH1A1 | |
| SCHEMBL14814067 | 0.75 | RAB9A (0.44) | RAB9AUSP2NPC1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809372-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2014-08-19 | — | — | US | claimed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533981-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160340310-A9 | Pyridine Derivatives | ENDO PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9371316-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-8809372-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809372-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809372-B2 | Pyridine derivatives | ASANA BIOSCIENCES, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2760833-A1 | PYRIDINE DERIVATIVES | Endo Pharmaceuticals Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049559-A1 | PYRIDINE DERIVATIVES | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085148-A1 | Pyridine Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085148-A1 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | RAB9A 3164/4885USP2 1959/4885NPC1 2147/4885 |
| US-20170073339-A1 | PYRIDINE DERIVATIVES | CYP21A2, CYP26A1, CYP11B1 | RAB9A 3120/4885USP2 2767/4885NPC1 2391/4885 |
| US-20160340310-A9 | Pyridine Derivatives | CYP2A7, CYP21A2, CYP3A7 | RAB9A 3164/4885USP2 1959/4885NPC1 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.